

Supplementary Information

Figure S1. ^1H NMR spectrum of 1	S2
Figure S2. Amplifying ^1H NMR spectrum of 1	S2
Figure S3. ^{13}C NMR spectrum of 1	S3
Figure S4. DEPT135 spectrum of 1	S3
Figure S5. HSQC spectrum of 1	S4
Figure S6. HMBC spectrum of 1	S4
Figure S7. NOESY spectrum of 1	S5
Figure S8. Amplifying NOESY spectrum of 1	S5
Figure S9. HRESIMS spectrum of 1	S6
Figure S10. IR spectrum of 1	S6
Figure S11. ^1H NMR spectrum of 2	S7
Figure S12. ^{13}C NMR and DEPT135 spectra of 2	S7
Figure S13. HSQC spectrum of 2	S8
Figure S14. HMBC spectrum of 2	S8
Figure S15. H-H COSY spectrum of 2	S9
Figure S16. NOESY spectrum of 2	S9
Figure S17. HRESIMS spectrum of 2	S10
Figure S18. IR spectrum of 2	S10
Figure S19. ^1H NMR spectrum of 3	S11
Figure S20. ^{13}C NMR and DEPT135 spectra of 3	S11
Figure S21. HSQC spectrum of 3	S12
Figure S22. HMBC spectrum of 3	S12
Figure S23. H-H COSY spectrum of 3	S13
Figure S24. NOESY spectrum of 3	S13
Figure S25. HRESIMS spectrum of 3	S14
Figure S26. IR spectrum of 3	S14
Figure S27. ^1H NMR spectrum of 9	S15
Figure S28. ^{13}C NMR spectrum of 9	S15
Figure S29. HSQC spectrum of 9	S16
Figure S30. HRESIMS spectrum of 9	S16
Figure S31. IR spectrum of 9	S17
Figure S32. ^1H NMR spectrum of 10	S17
Figure S33. ^{13}C NMR and DEPT135 spectra of 10	S18
Figure S34. HSQC spectrum of 10	S18
Figure S35. HMBC spectrum of 10	S19
Figure S36. H-H COSY spectrum of 10	S19
Figure S37. HRESIMS spectrum of 10	S20
Figure S38. IR spectrum of 10	S20
Figure S39. Comparison of the experimental CD spectra of 9 , 11 , 12	S21
S1. Isolation and purification of compounds 1–17	S21
S2. Structures of compounds 1–17	S22

Figure S1. ¹H-NMR spectrum of 1.




Figure S2. Amplifying ¹H-NMR spectrum of 1.




Figure S3. ¹³C-NMR spectrum of 1.




Figure S4. DEPT135 spectrum of 1.




Figure S5. HSQC spectrum of 1.




Figure S6. HMBC spectrum of 1.




Figure S7. NOE spectrum of 1.




Figure S8. Amplifying NOE spectrum of 1.




Figure S9. HR-ESIMS spectrum of 1.




Figure S10. IR spectrum of 1.




Figure S11. ¹H-NMR spectrum of 2.




Figure S12. ¹³C-NMR and DEPT135 spectra of 2.




Figure S13. HSQC spectrum of 2.




Figure S14. HMBC spectrum of 2.




Figure S15. ¹H-¹H COSY spectrum of 2.




Figure S16. NOE spectrum of 2.




Figure S17. HR-ESIMS spectrum of 2.




Figure S18. IR spectrum of 2.




Figure S19. ¹H NMR spectrum of 3.




Figure S20. ¹³C NMR and DEPT135 spectrum of 3.




Figure S21. HSQC spectrum of 3.




Figure S22. HMBC spectrum of 3.





Figure S23. ^1H - ^1H COSY spectrum of 3.

Figure S24. NOESY spectrum of 3.




Figure S25. HR-ESIMS spectrum of 3.




Figure S26. IR spectrum of 3.




Figure S27. ¹H NMR spectrum of 9.




Figure S28. ¹³C NMR spectrum of 9.




Figure S29. HSQC spectrum of 9.




Figure S30. HR-ESIMS spectrum of 9.




Figure S31. IR spectrum of 9.




Figure S32. ¹H-NMR spectrum of 10.




Figure S33. ¹³C NMR and DEPT135 spectra of 10.




Figure S34. HSQC spectrum of 10.




Figure S35. HMBC spectrum of 10.




Figure S36. ¹H-¹H COSY spectrum of 10.




Figure S37. HR-ESIMS spectrum of 10.




Figure S38. IR spectrum of 10.





Figure S39. Comparison of the experimental CD spectra of 9, 11, 12 and 4-(4-hydroxyphenyl)-5-(4-hydroxyphenylmethyl)-2-hydroxyfurane-2-one (18).



S1. Isolation and Purification of Compounds 1–17

The extract was subjected to silica gel CC using gradient elution with a $\text{CHCl}_3/\text{CH}_3\text{OH}$ solvent system at the ratios of 100:0, 98:2, 95:5, 90:10, 80:20, 50:50, and 0:100 (v/v) to give eight fractions (Fr.1–Fr.8). Fr.1 (3.9 g) was subjected to a silica gel CC eluting with $\text{CHCl}_3/\text{CH}_3\text{COCH}_3$ at the ratios of 90:10, 80:20, 70:30, 50:50, 100:0 (v:v), to offer Fr.1-1~8. Subfraction Fr.1-2 was isolated by MPLC with an ODS column, eluting with $\text{CH}_3\text{CN}-\text{H}_2\text{O}$ (from 10:90 to 100:0, 90 min, 20 mL/min) to give Fr.1-2-1~6. Subfraction Fr.1-2-5 was purified by SP-RP HPLC, eluting with $\text{CH}_3\text{CN}/\text{H}_2\text{O}$ (37:53), to obtain **13** ($t_R = 55$ min, 15 mg). Subfraction Fr.1-2-6 was purified by SP-RP HPLC, eluting with $\text{CH}_3\text{CN}/\text{H}_2\text{O}$ (65:35), to obtain **6** ($t_R = 77$ min, 2 mg). Subfraction Fr.1-3 was purified by SP-RP HPLC, eluting with $\text{CH}_3\text{OH}/\text{H}_2\text{O}$ (60:40), to obtain **12** ($t_R = 70$ min, 15 mg), **4** ($t_R = 53$ min, 15 mg). Subfraction Fr.1-5 was purified by SP-RP HPLC, eluting with $\text{CH}_3\text{OH}/\text{H}_2\text{O}$ (55:45), to obtain **17** ($t_R = 30$ min, 3 mg), **7** ($t_R = 60$ min, 4 mg). Subfraction Fr.1-6 was isolated by MPLC with an ODS column, eluting with $\text{CH}_3\text{CN}-\text{H}_2\text{O}$ (from 10:90 to 100:0, 60 min, 20 mL/min) to give Fr.1-6-1~4. Fr.1-6-3 was purified by SP-RP HPLC, eluting with $\text{CH}_3\text{OH}/\text{H}_2\text{O}$ (70:30), to obtain **8** ($t_R = 33$ min, 2 mg), **3** ($t_R = 41$ min, 4 mg). Subfraction Fr.1-7 was isolated by MPLC with an ODS column, eluting with $\text{CH}_3\text{CN}-\text{H}_2\text{O}$ (from 10:90 to 100:0, 60 min, 20 mL/min) to give Fr.1-7-1~4. And subfraction Fr.1-7-2 was purified by SP-RP HPLC, eluting with $\text{CH}_3\text{CN}/\text{H}_2\text{O}$ (45:55), to obtain **1** ($t_R = 36$ min, 3 mg), **5** ($t_R = 45$ min, 6 mg), **2** ($t_R = 47$ min, 4 mg). Fr.2 (11 g) was subjected to a silica gel CC eluting with $\text{CHCl}_3/\text{CH}_3\text{COCH}_3$ at the ratios of 90:10, 80:20, 70:30, 50:50, 100:0 (v:v), to offer Fr.2-1~6. Subfraction Fr.2-2 was separated by MPLC with an ODS column, eluting with $\text{CH}_3\text{OH}-\text{H}_2\text{O}$ (from 10:90 to 100:0, 60 min, 20 mL/min) to give Fr.2-2-1~3. And subfraction Fr.2-2-1 was purified by SP-RP HPLC, eluting with $\text{CH}_3\text{CN}/\text{H}_2\text{O}$ (57:43), to obtain **14** ($t_R = 30$ min, 10 mg). Fr.4 (1.45 g) was isolated by MPLC with an ODS column, eluting with $\text{CH}_3\text{OH}-\text{H}_2\text{O}$ (from 15:85 to 100:0, 90 min, 20 mL/min) to give Fr.4-1~5. Fr.4-5 was

purified by SP-RP HPLC, eluting with CH₃CN/H₂O (46:54), to afford **11** (*t_R* = 23 min, 30 mg) and **9** (*t_R* = 19.0 min, 4 mg). Fr.5 (1.2 g) was isolated by MPLC with an ODS column, eluting with CH₃OH-H₂O (from 15:85 to 100:0, 90min, 20 mL/min) to give Fr.5-1~5. Subfraction Fr.5-3 was purified by SP-RP HPLC, eluting with CH₃OH/H₂O (55:45), to obtain **10** (*t_R* = 39 min, 8 mg). Fr.7 (3 g) was subjected to Sephadex LH-20 CC eluting with CH₃OH to collect Fr.7-1~4. Further subfraction Fr.7-4 (1.8 g) was isolated by MPLC with an ODS column, eluting with CH₃OH-H₂O (from 15:85 to 100:0, 90 min, 20 mL/min) to give Fr.7-4-1~4. And then subfraction Fr.7-4-4 was purified by SP-RP HPLC, eluting with CH₃OH/H₂O (63:37), to obtain **15** (*t_R* = 37 min, 8 mg), **16** (*t_R* = 14 min, 6 mg).

S2. Structures of Compounds 1–17

